Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | KIF11 | P52732 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7590755 | 0.84 | ALDH1A1 (0.61) | TYMSMAPTPOLBKDM4EHPGD | |
| SCHEMBL29438978 | 0.84 | ALDH1A1 (0.61) | TYMSMAPTPOLBKDM4EHPGD | |
| SCHEMBL30798863 | 0.81 | TNKS2 (0.48) | MAPTPOLBKDM4EHPGDALDH1A1 | |
| SCHEMBL30848085 | 0.80 | IDO1 (0.43) | TYMSMAPTPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL29172059 | 0.80 | IDO1 (0.43) | TYMSMAPTPOLBRAB9ASMN1; SMN2 | |
| SCHEMBL25457211 | 0.79 | RAB9A (0.53) | MAPTPOLBKDM4EHPGDALDH1A1 | |
| SCHEMBL1170649 | 0.79 | KDM4E (0.52) | KDM4EHPGDALDH1A1HSD17B10RAB9A | |
| SCHEMBL12540 | 0.79 | ALDH1A1 (0.50) | MAPTPOLBKDM4EHPGDALDH1A1 | |
| SCHEMBL14765152 | 0.78 | BRD4 (0.53) | TYMSKDM4EKEAP1NFE2L2 | |
| SCHEMBL12052868 | 0.78 | POLB (0.51) | MAPTPOLBKDM4EHPGDALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 100 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | claimed |
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2025-09-09 | — | — | US | disclosed |
| CN-119425419-A | Metal-organic framework composite membrane for helium and methane mixed gas separation and preparation method and application thereof | 苏州大学 | 2025-02-14 | — | — | CN | disclosed |
| EP-3608312-B1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND APPLICATIONS THEREOF | XIAMEN VIVOHEALTHS TECH CO LTD (CN) | 2024-06-26 | — | — | EP | disclosed |
| WO-2024129614-A1 | SOMATOSTATIN SUBTYPE-2 RECEPTOR (SST2R) TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2024-06-20 | — | — | WO | disclosed |
| EP-3475275-B1 | 3-ARYL AND HETEROARYL SUBSTITUTED 5-TRIFLUOROMETHYL OXADIAZOLES AS HISTONE DEACETYLASE 6 (HDAC6) INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-04-10 | — | — | EP | disclosed |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| EP-3752498-B1 | SOMATOSTATIN MODULATORS AND USES THEREOF | CRINETICS PHARMACEUTICALS INC (US) | 2023-06-28 | — | — | EP | disclosed |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | XIAMEN VIVOHEALTHS TECHNOLOGY CO., LTD. (CN) | 2023-02-21 | — | — | US | disclosed |
| WO-2022261235-A1 | NON-PEPTIDE TARGETED THERAPEUTICS AND USES THEREOF | Crinetics Pharmaceuticals, Inc. (US) | 2022-12-15 | — | — | WO | disclosed |
| US-5274094-A | Diseases or conditions mediated by platelet-activating factor; cyclization of a diamino compound with a carboxylic acid | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-12-28 | — | — | US | disclosed |
| EP-0543861-A1 | IMIDAZOPYRIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| EP-0543858-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIOTECH PHARMACEUTICALS LIMITED (GB) | 1993-06-02 | — | — | EP | disclosed |
| US-5200412-A | Antiinflammatory agents and antiallergens | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-04-06 | — | — | US | disclosed |
| US-5196440-A | Compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.P.A. (IT) | 1993-03-23 | — | — | US | disclosed |
| US-5180723-A | Hypertensives, bronchodilators, antiedemic agents | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1993-01-19 | — | — | US | disclosed |
| WO-1992003422-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| WO-1992003423-A1 | BENZIMIDAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND APPLICATION | BRITISH BIO-TECHNOLOGY LIMITED (GB) | 1992-03-05 | — | — | WO | disclosed |
| US-4940800-A | Beazimidazole compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.P.A. (IT) | 1990-07-10 | — | — | US | disclosed |
| EP-0352864-A2 | Compounds active as inhibitors of the cholesterol biosynthesis | ZAMBON GROUP S.p.A. (IT) | 1990-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12410142-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | TYMS 1367/4885MAPT 82/4885POLB 2083/4885 |
| US-11584722-B2 | Substituted imidazole salt compounds, preparation method thereof, pharmaceutical composition thereof and application thereof | ALDOA, IDE, ACAT1 | TYMS 1367/4885MAPT 82/4885POLB 2083/4885 |
| US-20230202986-A1 | SUBSTITUTED IMIDAZOLE SALT COMPOUNDS, PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION THEREOF AND APPLICATION THEREOF | ALDOA, IDE, ACAT1 | TYMS 1367/4885MAPT 82/4885POLB 2083/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.